Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Benign Liver Optimal Core Study (Tissue Acquisition Comparison in Benign Liver Disease)
NCT03245580 · View on ClinicalTrials.gov ↗
Study Summary
The primary purpose of this prospective, randomized, multicenter study is to evaluate and compare the amount and quality of tissue samples yielded in a liver biopsy comparing 2 different techniques of EUS guided CORE liver biopsy for benign disease. The two techniques: "modified Wet suction" and "Slow pull" technique of collecting tissue from a liver biopsy via Endoscopic Ultrasound (EUS).
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Core Liver Biopsy
Study Locations (7)
Indiana
- Parkview Regional Medical Center — Fort Wayne
- Indiana University — Indianapolis
Alabama
- University South Alabama — Mobile
California
- Santa CLara Valley Medical Center — San Jose
Louisiana
- Oschner Health System — New Orleans
Pennsylvania
- Geisinger Medical Center — Danville
Texas
- Baylor Medical Center — Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 2018-03-08 |
| Est. Completion | 2020-09-15 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03245580
The ClinicalTrials.gov registry entry for NCT03245580 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 153 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Parkview Health, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Liver Diseases appearing as the primary indexed condition, and to 1 intervention — of which Core Liver Biopsy is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT03245580 reports 7 study locations spanning 6 distinct geographic areas — top geographies include Indiana, Alabama, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT03245580 about?
NCT03245580 is a clinical study titled "Benign Liver Optimal Core Study (Tissue Acquisition Comparison in Benign Liver Disease)". The primary purpose of this prospective, randomized, multicenter study is to evaluate and compare the amount and quality of tissue samples yielded in a liver biopsy comparing 2 different techniques of EUS guided CORE liver biopsy for benign disease. The two techniques: "modified Wet suction" and "Sl...
What is the current status of trial NCT03245580?
This trial is currently completed. It is a NA study. The enrollment target is 153 participants. The study started on 2018-03-08. Estimated completion is 2020-09-15.
What conditions does trial NCT03245580 study?
This clinical trial studies the following conditions: Liver Diseases. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT03245580?
The interventions under investigation include: Core Liver Biopsy (DIAGNOSTIC_TEST). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT03245580?
This trial is sponsored by Parkview Health, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT03245580 being conducted?
This trial has 7 study locations across Alabama, California, Indiana, Louisiana, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.